Navigation Links
The findings between DNMs and autism provides global view of mutability on human diseases
Date:12/21/2012

December 21, 2012, Shenzhen, China A study published online in Cell reports the latest investigation of de novo germline mutation by whole genome sequencing in autism patients. This study provides a global view of the landscape of mutability and its influence on genetic diversity and susceptibility in autism, and its implications on other human diseases. The work was a collaborative effort led by international teams comprised of the University of California, San Diego, BGI, and other institutes. The results are expected to shed new light on a deeper understanding of the mechanisms underlying genome evolution and human diseases.

Mutation plays an important role in human diseases, such as Autism Spectrum Disorders (ASDs). Many cases for ASDs are caused by de novo mutations that are not inherited, but arise spontaneously in the ovum, sperm or fertilized egg. Epidemiologists have reported a higher risk of autism in children with older fathers, but so far there has been few biological evidence to support this theory. To comprehensively explore the genetics of ASDs, it is vital to understand the mutational process and how the de novo germline mutation impacts ASDs.

In this study, researchers applied whole genome sequencing (WGS) approach to characterize patterns of de novo germline mutations (DNMs). A total of 581 DNMs were identified from ten monozygotic twins that suffered from ASDs by comparing with their unaffected parents. To better understand the paternal age effects on mutation rate, the twins were separated into two groups, one with younger fathers (<30 years old), and the other with older fathers (>40 years old). The results showed that paternal age accounted for a substantial portion of variability in mutation that happened in offspring, while maternal age has no significant effect.

Mutation is a random process. However, researchers in this study found DNMs displayed a remarkably non-random positioning in the genome and spaced more closely than their expectation. More importantly, the distribution of de novo germline mutation can be explained by characteristics of the genome. Clusters of new mutations could be explained by allelic gene conversion or compound mutation. Clustering on larger scales could be explained by mutation-rate variation. The regional mutation rates are subject to a combination of influences, including DNase hypersensitivity, GC content, nucleosome occupancy, recombination rate, simple repeats, the trinucleotide sequence surrounding the site, among others.

Researchers further examined the landscape of mutability throughout the genome, including hotspots with highly elevated mutability, and warm spots with moderately increased mutability. They found some strong evidences to support that hypermutability is a characteristic of disease genes. Intriguingly, they found the mostly highly mutable sequences in the genome are the most highly conserved. This finding has not been reported in the previous studies.

Another interesting result was that the genes impacted by DNMs in twins demonstrated a significant association with autism in other independent projects. These findings suggest that regional hypermutability is a significant factor shaping patterns in genetic variation and disease risk in humans.

Yujian Shi, Project Manager of BGI, said, "The study opens a new way for pedigree studies on neurological diseases and rare diseases. The novel approach and results here will help to massively analyze lineage or sporadic autism population. We found there was a significant relationship between human diseases and individual genetic variation model shaped by DNMs derived regional hypermutability. Furthermore, the discovery of a large number of novel autism susceptibility genes will lay a solid foundation for the early diagnosis and treatment of autism."


'/>"/>
Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
2. Verinata Health Announces New Findings At The American Society Of Human Genetics
3. New findings on gene regulation and bone development
4. New findings on protein misfolding
5. Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science
6. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
7. New menhaden study will help identify balance between fishing and preserving Bay forage fish
8. Dark Ages scourge enlightens modern struggle between man and microbes
9. Multiple sclerosis immune exchange between brain and blood is uncovered
10. Researchers study links between conflict and fisheries in East Africa
11. Mongolia and the Altai Mountains: Origins of genetic blending between Europeans and Asians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
Breaking Biology Technology: